<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 20-30% of <z:hpo ids='HP_0003002'>breast cancers</z:hpo>, improves the prognosis in women affected by this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>In this review, we discuss the pathophysiology of trastuzumab <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and the complex interplay between ErbB2 inhibition and <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research </plain></SENT>
</text></document>